Charles Mesguich

Publication Activity (10 Years)

Years Active: 2016-2021
Publications (10 Years): 7

Top Topics

Diffusion Weighted

Positron Emission Tomography

Multiple Myeloma

Top Venues

British journal of haematology

Annals of hematology

JMIR research protocols

This page only lists publications with an associated author ORCID identifier.

Publications

Charles Mesguich, Valérie Latrabe, Cyrille Hulin, Axelle Lascaux, Laurence Bordenave, Elif Hindié, Gerald Marit
Prospective Comparison of 18-FDG PET/CT and Whole-Body MRI with Diffusion-Weighted Imaging in the Evaluation of Treatment Response of Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant. Cancers 13 (8) (2021)
Charles Mesguich, Cyrille Hulin, Axelle Lascaux, Laurence Bordenave, Gerald Marit, Elif Hindié
Choline PET/CT in Multiple Myeloma. Cancers 12 (6) (2020)
Charles Mesguich, Cyrille Hulin, Valerie Latrabe, Axelle Lascaux, Laurence Bordenave, Elif Hindié, Gerald Marit
Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma. Annals of hematology 99 (12) (2020)
Charles Mesguich, Cyrille Hulin, Valerie Latrabe, Julien Asselineau, Laurence Bordenave, Paul Perez, Elif Hindié, Gerald Marit
Prospective Comparison of 18F-Choline Positron Emission Tomography/Computed Tomography (PET/CT) and 18F-Fluorodeoxyglucose (FDG) PET/CT in the Initial Workup of Multiple Myeloma: Study Protocol of a Prospective Imaging Trial. JMIR research protocols 9 (9) (2020)
Charles Mesguich, Alexandre Roch, Elif Hindié, Noël Milpied, Laurence Bordenave, Ghoufrane Tlili, Krimo Bouabdallah
Prognostic utility of pre-transplantation [18 F] fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma who underwent rituximab, dexamethasone, high-dose cytarabine, carboplatin salvage chemotherapy. British journal of haematology 188 (2) (2019)
Charles Mesguich, Anne-Laure Cazeau, Krimo Bouabdallah, Elif Hindié
Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations? - Response to Adams & Kwee. British journal of haematology 181 (1) (2017)
Charles Mesguich, Anne-Laure Cazeau, Krimo Bouabdallah, Pierre Soubeyran, Martine Guyot, Noël Milpied, Laurence Bordenave, Elif Hindié
Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation. British journal of haematology 175 (4) (2016)